Oregon Health & Science University

Targeting signaling and epigenetic dysfunction in CSF3R-driven leukemias

May 11, 2020

Research in my laboratory is centered on uncovering the biochemical, signaling, and epigenetic defects that drive myeloid disorders. Our long-term goal is to harness this mechanistic understanding to facilitate the development of better treatments for patients. Our group is part of the Knight Cancer Institute at Oregon Health and & Science University, located in beautiful Portland, Oregon.


myeloid leukemia, CSF3R, epigenetic regulation, targeted therapies

%d bloggers like this: